Placebo 50 mg

DRUG3 trials

Sponsors

Janssen Pharmaceutical K.K., Guangdong Zhongsheng Pharmaceutical Co., Ltd., Hongyan Wu

Conditions

MAFLDNonalcoholic Steatohepatitis (NASH)Psoriasis

Phase 1

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

CompletedNCT03392779

Guangdong Zhongsheng Pharmaceutical Co., Ltd.Nonalcoholic Steatohepatitis (NASH)

Start: 2018-01-05End: 2019-03-22Updated: 2019-08-13

Phase 3

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

CompletedNCT02325219

Janssen Pharmaceutical K.K.Psoriasis

Start: 2014-12-19End: 2019-02-08Updated: 2020-05-22

Unknown Phase

Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Not yet recruitingNCT07199933

Hongyan WuMAFLD

Start: 2025-10-01End: 2027-10-31Target: 74Updated: 2025-09-30

Related Papers

Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.

2023-10-3131 citations

Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study

Expert Opinion on Investigational Drugs2021-03-086 citations